Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Metabolically Flexible CAR T Cells (mfCAR-T), with Constitutive Expression of PGC-1α Resistant to Post Translational Modifications, Exhibit Superior Survival and Function in Vitro

Reginald M Atkins, PhD, Meghan A Menges, Alexis Bauer, BS, Joel G. Turner, PhD, Frederick L. Locke, MD

Blood (2020) 136 (Supplement 1): 30.

https://doi.org/10.1182/blood-2020-143217

Published: 2020

Journal Articles

The Result of a Phase 1 Study of Selinexor in Combination with High-Dose Melphalan and Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Taiga Nishihori, MD, Melissa Alsina, MD, Jose Ochoa, MD, Omar Alexis Castaneda Puglianini, MD, Rachid Baz, MD, Kenneth H. Shain, MD PhD, Jason B. Brayer, PhDMD, Jongphil Kim, PhD, Michael Dumala, Joel G. Turner, PhD, Daniel M Sullivan, MD

Blood (2019) 134 (Supplement_1): 3314.

https://doi.org/10.1182/blood-2019-131321

Published: 2019

Journal Articles

Deep and Durable Responses with Selinexor, Daratumumab, and Dexamethasome (SDd) in Patients with Multiple Myeloma (MM) Previously Exposed to Proteasome Inhibitors and Immunomodulatory Drugs: Results of Phase 1b Study of SDd

Blood (2018) 132 (Supplement 1): 599.

https://doi.org/10.1182/blood-2018-99-117201

Published: 2018

Journal Articles

Phase I/II Study of Liposomal Doxorubicin (DOX) in Combination with Selinexor (SEL) and Dexamethasone (Dex) for Relapsed and Refractory Multiple Myeloma (RRMM)

Rachid Baz, MD, Jeffrey A Zonder, MD, Kenneth H Shain, MD PhD, Melissa Alsina, MD, Jason B. Brayer, PhDMD, Mark Melody, Joel G. Turner, PhD, Jana L Dawson, Jongphil Kim, Daniel M Sullivan, MD

Blood (2017) 130 (Supplement 1): 3095.

https://doi.org/10.1182/blood.V130.Suppl_1.3095.3095

Published: 2017

Journal Articles

A Phase 1/2 Study of the Second Generation Selective Inhibitor of Nuclear Export (SINE) Compound, KPT-8602, in Patients with Relapsed Refractory Multiple Myeloma

R. Frank Cornell, MD MS, Adriana C Rossi, MD, MSc, Rachid Baz, MD, Craig C Hofmeister, Chaim Shustik, MD, Joshua R. Richter, MD, Christine Chen, MD, Dan T. Vogl, MD, Sharon Shacham, PhD MBA, Erkan Baloglu, PhD MBA, William Senapedis, PhD, Joel Ellis, PhD, Sharon Friedlander, PhD, Cassandra Choe-Juliak, MD, Christopher L Cubitt, PhD, Joel G Turner, PhD, Daniel Sullivan, MD MS, Michael Kauffman, MD PhD

Blood (2016) 128 (22): 4509.

https://doi.org/10.1182/blood.V128.22.4509.4509

Published: 2016

Journal Articles

The Synergistic Effect of Melphalan and XPO1 Inhibition in Pre-Clinical Models of Multiple Myeloma

Yan Cui, MD, Joel G Turner, PhD, Jana L Dawson, BS, Juan A Gomez, BS, Kenneth H. Shain, MD PhD, Mark B Meads, PhD, Erkan Baloglu, PhD, William S. Dalton, PhD MD, Taiga Nishihori, MD, Daniel M Sullivan, MD

Blood (2016) 128 (22): 5662.

https://doi.org/10.1182/blood.V128.22.5662.5662

Published: 2016

Journal Articles

Combination Therapy with Bortezomib or Carfilzomib and Selinexor Induces Nuclear Localization of Ikbα and Overcomes Acquired Proteasome Inhibitor Resistance in Human Multiple Myeloma

Joel G Turner, PhD, Trinayan Kashyap, MS, Jana L Dawson, BS, Juan A Gomez, BS, Alexis Bauer, BS, Steven Grant, MD, Yun Dai, PhD, Kenneth H. Shain, MD PhD, Mark B Meads, PhD, Yosef Landesman, PhD, Daniel M Sullivan, MD

Blood (2016) 128 (22): 3299.

https://doi.org/10.1182/blood.V128.22.3299.3299

Published: 2016

Journal Articles

Combination Therapy of Selinexor with Bortezomib or Carfilzomib Overcomes Drug Resistance to Proteasome Inhibitors (PI) in Human Multiple Myeloma

Daniel M Sullivan, MD, Trinayan Kashyap, MS, Jana L Dawson, BS, Yosef Landesman, PhD, Steven Grant, MD, Kenneth H. Shain, MD PhD, Yun Dai, PhD, Michael Kauffman, MD PhD, Sharon Shacham, Joel G Turner, PhD

Blood (2015) 126 (23): 3048.

https://doi.org/10.1182/blood.V126.23.3048.3048

Published: 2015

Journal Articles

Next Generation XPO1 Inhibitor KPT-8602 for the Treatment of Drug-Resistant Multiple Myeloma

Joel G Turner, PhD, Jana L Dawson, BS, Christopher L Cubitt, PhD, Erkan Baluglo, PhD, Steven Grant, MD, Yun Dai, PhD, Kenneth H Shain, MD PhD, William S. Dalton, PhD MD, Sharon Shacham, William Senapedis, PhD, Daniel M Sullivan, MD

Blood (2015) 126 (23): 1818.

https://doi.org/10.1182/blood.V126.23.1818.1818

Published: 2015

Journal Articles

Melphalan and XPO1 Inhibitor Combination Therapy for the Treatment of Multiple Myeloma

Joel G Turner, PhD, Jana L Dawson, BS, Steven Grant, MD, Kenneth H. Shain, MD PhD, Yun Dai, MD PhD, Chris Cubitt, PhD, Rachid Baz, MD, Taiga Nishihori, MD, Michael Kauffman, MD PhD, Sharon Shacham, PhD MBA, Daniel M Sullivan, MD

Blood (2014) 124 (21): 2084.

https://doi.org/10.1182/blood.V124.21.2084.2084

Published: 2014

Journal Articles

Targeting The Nuclear Export Signal In Multiple Myeloma

Joel G Turner, PhD, Thomas C Rowe, PhD, David Ostrov, PhD, Jana L Dawson, BS, Danielle Pernazza, PhD, Nicholas J Lawrence, Ph.D., Daniel M Sullivan, MD

Blood (2013) 122 (21): 1925.

https://doi.org/10.1182/blood.V122.21.1925.1925

Published: 2013

Journal Articles

Casein Kinase II Modulates Topoisomerase II Alpha Nuclear Export and Drug Sensitivity in Multiple Myeloma

Joel G Turner, PhD, Jana L Dawson, BS, Daniel M Sullivan, MD

Blood (2012) 120 (21): 4032.

https://doi.org/10.1182/blood.V120.21.4032.4032

Published: 2012

Journal Articles

Novel Drug Targets to Overcome De Novo Drug-Resistance In Multiple Myeloma

Joel G Turner, PhD, Thomas C Rowe, PhD, David Ostrov, Jana L Dawson, BS, Elizabeth Ciaravino, BS, Daniel Sullivan, MD

Blood (2010) 116 (21): 3006.

https://doi.org/10.1182/blood.V116.21.3006.3006

Published: 2010

Journal Articles

Preclinical Development of Small-Molecule CRM1 Inhibitors as Novel Therapy for the Treatment of Myeloma and Other Hematological Malignancies

Sharon Shacham, PhD, MBA, Joel G Turner, PhD, Raphael Nir, Giulio Draetta, Vincent Sandanayaka, Sharon Shechter, Michael Kauffman, Daniel Sullivan, MD

Blood (2010) 116 (21): 3012.

https://doi.org/10.1182/blood.V116.21.3012.3012

Published: 2010

NARROW

Metabolically Flexible CAR T Cells (mfCAR-T), with Constitutive Expression of PGC-1α Resistant to Post Translational Modifications, Exhibit Superior Survival and Function in Vitro

The Result of a Phase 1 Study of Selinexor in Combination with High-Dose Melphalan and Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Deep and Durable Responses with Selinexor, Daratumumab, and Dexamethasome (SDd) in Patients with Multiple Myeloma (MM) Previously Exposed to Proteasome Inhibitors and Immunomodulatory Drugs: Results of Phase 1b Study of SDd

Phase I/II Study of Liposomal Doxorubicin (DOX) in Combination with Selinexor (SEL) and Dexamethasone (Dex) for Relapsed and Refractory Multiple Myeloma (RRMM)

A Phase 1/2 Study of the Second Generation Selective Inhibitor of Nuclear Export (SINE) Compound, KPT-8602, in Patients with Relapsed Refractory Multiple Myeloma

The Synergistic Effect of Melphalan and XPO1 Inhibition in Pre-Clinical Models of Multiple Myeloma

Combination Therapy with Bortezomib or Carfilzomib and Selinexor Induces Nuclear Localization of Ikbα and Overcomes Acquired Proteasome Inhibitor Resistance in Human Multiple Myeloma

Combination Therapy of Selinexor with Bortezomib or Carfilzomib Overcomes Drug Resistance to Proteasome Inhibitors (PI) in Human Multiple Myeloma

Next Generation XPO1 Inhibitor KPT-8602 for the Treatment of Drug-Resistant Multiple Myeloma

Melphalan and XPO1 Inhibitor Combination Therapy for the Treatment of Multiple Myeloma

Targeting The Nuclear Export Signal In Multiple Myeloma

Casein Kinase II Modulates Topoisomerase II Alpha Nuclear Export and Drug Sensitivity in Multiple Myeloma

Novel Drug Targets to Overcome De Novo Drug-Resistance In Multiple Myeloma

Preclinical Development of Small-Molecule CRM1 Inhibitors as Novel Therapy for the Treatment of Myeloma and Other Hematological Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only